58results about How to "Long-lasting immunity" patented technology

Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.

The invention relates to an Asia1 type foot-and-mouth disease recombinant virus without pathogenicity for a host and a preparation method and application thereof. A saving system is efficient eukaryotic plasmids which are constructed by gene engineering and can express exact foot-and-mouth disease virus genome RNA (Ribonucleic Acid), and therefore the foot-and-mouth disease recombinant virus can be constructed and prepared; vaccine strains with high titer and good antigen matching property can be prepared by using the plasmids, can be prepared into live vaccines or inactivated vaccines and can effectively stimulate bodies to produce immune response after being used for immunizing pigs and cattle, provide an immune protective effect on the pigs and the cattle and effectively protect GV and GII prevalent strains, the immune protection rate can reach 100 percent, and the median protective dose (PD50) is 6.34 to 13.59; and the recombinant virus has the advantages of high titer, high antigen matching property with the prevalent strains, wide antigen spectrum and high immune protection rate, does not have pathogenicity for pig and cattle hosts, does not form toxemia or expel toxin, and can be applied to prevention and control of Asia1 type foot-and-mouth disease viruses of China and neighboring countries.

The invention relates to a bivalent inactivated vaccine for bovine multocida pasteurellosis, belonging to the technical field of preparation of veterinary biological products. The bivalent inactivatedvaccine provided by the invention is composed of antigens and a vaccine adjuvant, wherein the antigens are a bovine multocida pasteurellosis capsular type-A Pm-TJ strain and a bovine multocida pasteurellosis capsular type-B C45-2 strain. For the bivalent inactivated vaccine prepared by adopting the method provided by the invention, the concentration purifying process is adopted, the fermentationculture process of the bovine multocida pasteurellosis capsular type-B C45-2 strain is optimized, so that the fermentation time is shortened by one half, and the production efficiency is improved. Forthe bivalent inactivated vaccine provided by the invention, the bovine fibrinous and suppurative pneumonia and bovine hemorrhagic septicemia caused by bovine pasteurella multocida infection can be prevented through one-time injection immunization, and the bivalent inactivated vaccine has the features of safety, reliability and good immune effect.

The invention discloses an apple vinegar health drink capable of improving immunity. The apple vinegar health drink is prepared by the following raw materials: 0.2-0.5% of dioscoreae rhizome extract, 0.05-0.2% of achyranthes bidentata extract, 0.1-0.3% of radix rehmanniae extract, 0.1-0.3% of poria cocos extract, 1.5-4% of original apple vinegar, 2-4% of concentrated apple juice, 0.4-1% of concentrated haw juice, 0.2-0.8% of honey, 0.01-0.025% of sucralose and the balance of water. The apple vinegar health drink is prepared by the five extracts of traditional Chinese medicines including dioscoreae rhizome, achyranthes bidentata, radix rehmanniae, poria cocos and chrysanthemum which have the function of improving immunity according to the scientific proportion, the extracts of traditional Chinese medicines are supplemented by the original apple vinegar, the apple juice, the haw juice and the honey, reasonable compatibility is carried out on the raw materials, and the natural sweetener-sucralose is added into the raw materials for seasoning. The apple vinegar health drink not only can meet the demand of the people with low immunity for the delicious mouthfeel under the condition of controlling excessive sugar intake, but also more importantly utilizes the traditional Chinese medicines to carry out symptomatic treatment and comprehensive conditioning on the human body and utilizes the comprehensive functions such as nutritional supplement of fruit juice and fruit vinegar, thus achieving the health care effect of improving immunity.

The invention provides a porcine circovirus 2 and porcine circovirus 3 bivalent inactivated vaccine and a preparation method thereof. The bivalent inactivated vaccine comprises inactivated porcine circovirus 2 and 3 and a vaccine adjuvant, wherein the content of the porcine circovirus 2 and 3 is respectively at least 105.5 TCID50 / piece. The bivalent inactivated vaccine disclosed by the invention has the following advantages that the immune effect of the porcine circovirus 2 is equivalent to or better than that of a commercial vaccine, a porcine circovirus 3 commercial vaccine does not exist inthe market, and two antigens do not interfere with each other; the immune duration is long, and the efficacy is lasting; and only one shot immunization is needed, the cost is reduced, and stress reactions of animals are reduced. The bivalent inactivated vaccine disclosed by the invention can be applied to simultaneously preventing the porcine circovirus 2 and 3.

The invention provides a foot-and-mouth disease virus-like particle antigen. The foot-and-mouth disease virus-like particle antigen consists of a VP0 antigen protein, a VP1 antigen protein and a VP3 antigen protein through assembling, wherein the VP0 antigen protein is coded by a nucleotide sequence as shown in Seq ID No.1 or coded by a degenerate sequence of the nucleotide sequence as shown in Seq ID No.1, the VP1 antigen protein is coded by a nucleotide sequence as shown in Seq ID No.3 or coded by a degenerate sequence of the nucleotide sequence as shown in Seq ID No.3, and the VP3 antigen protein is coded by a nucleotide sequence as shown in Seq ID No.2 or coded by a degenerate sequence of the nucleotide sequence as shown in Seq ID No.2. The foot-and-mouth disease virus-like particle antigen has favorable immunogenicity, a vaccine composition prepared from the foot-and-mouth disease virus-like particle antigen can protect current epidemic O-type Ind strains through one-time immunization, and the immunoprotection period is long. The invention further provides the vaccine composition prepared from the foot-and-mouth disease virus-like particle antigen, and a preparation method andan application of the vaccine.

The invention discloses a Brucella deoxyribonucleic acid (DNA) vaccine and a construction method thereof as well as the application of the vaccine. The Brucella DNA vaccine disclosed by the invention contains Brucella P39 and 18KD genes which can also be co-expressed in eukaryotic cells by internal ribosome entry site (IRES) mediation. The Brucella DNA vaccine disclosed by the invention has an SEQ1 gene sequence. According to the Brucella DNA vaccine and the construction method thereof, which are disclosed by the invention, the total DNA of Brucella abortus 2 type CVCC 12 is taken as a template, a polymerase chain reaction is carried out by using P39S primers SEQ2 and SEQ3 and 18KDS primers SEQ4 and SEQ5 respectively so as to obtain a target gene, and then the target gene is converted into a JM109 competent cell after being cleaved so as to obtain positive plasmid named as pQC-P39 / 18KD. Then, the pQC-P39 / 18KD and pcDNA3.1 plasmid are connected by using a T4DNA ligase after being cleaved, and afterwards are converted into E.coli DH5 alpha so as to obtain pcDNA-P39 / 18KD recombinant plasmid.

The invention relates the attenuated strain used for preparing pasteurella multocid vaccine, which is pasteurella multocid B26-T1200. The method comprises the following steps: adding the virulent strain B26 into martin soup containing the 0.1% splitting sheep whole blood to propagate at 37-45Deg.C, measuring the virulence and immunity of passage strain, and getting the pasteurella multocid B26-T1200 at the 1200 generation. The pasteurella multocid vaccine used by the said attenuated strain has high safety, good stability, and long immunity duration. The minimum immunizing dose of the strain is 13,000,000 viable bacteria.

The invention provides a goat contagious pleuropneumonia subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of preparation of animal infectious disease vaccines, and a mycoplasma capricolum subsp.capripneumonia immune protein combination comprises mycoplasma capricolum subsp.capripneumonia immune proteins A, B, C, D and E; the mass ratio of the mycoplasma capricolum subsp.capripneumoniae immune proteins A to B to C to D to E is (0.5 to 1.5): (0.5 to 1.5): (0.5 to 1.5): (0.5 to 1.5): (0.5 to 1.5); and the goat contagious pleuropneumonia subunit vaccine comprises the goat mycoplasma goat pneumonia subspecies immune protein combination and an adjuvant. The subunit vaccine has the advantages of high safety, good immune effect, good stability and small side reaction.

The invention discloses a rabies vaccine for human use. The rabies vaccine is characterized by comprising a rabies virus inactivated vaccine material and a compound adjuvant, wherein the compound adjuvant is composed of zinc hydroxide colloid, squalene, hyaluronic acid and Tween-80; each dosage of the rabies virus inactivated vaccine material uses 0.1-10mg of zinc hydroxide colloid, 10-1000 mug of squalene, and 10-1000 mug of hyaluronic acid, and 10-1000 mug of Tween-80. With the adoption of the compound adjuvant, the immune response time is greatly prolonged, the neutralization is rapidly generated, the immuning capacity lasts for a long time, meanwhile, the preparation technology is simple, the needed equipment is easily available, the industrial production cost is reduced greatly, and the stability of the obtained rabies vaccine is also greatly improved.

The invention relates to a long-acting animal rabies vaccine and a preparing method thereof. Replication-defective retrovirus is used as a carrier. After forming a virus infection organism, the carrier can be integrated into a chromosome of a host cell. An expression cassette for expressing a rabies virus glycosidoprotein is used as an exogenous target gene, and the protein expressed by the target gene can stimulate the organism to produce the immune response to the rabies virus. By converting the packaging cell of the retrovirus, recombinant viruses can be continuously produced to recombineviruses and immune animals, and therefore the animals can obtain long-term immune protection effect on the rabies. The recombinant vaccine has the advantages of wide applicable range for animals, safe use, and long duration time of the induced immune effective period, and is a novel long-effective vaccine for preventing rabies.

The invention discloses a human rabies vaccine, which is characterized in that it contains raw materials of inactivated rabies virus vaccine and a composite adjuvant, wherein the composite adjuvant is composed of zinc hydroxide colloid, lanolin, bacterial lipopolysaccharide and Tween-80; The raw materials of the rabies virus inactivated vaccine described in the dosage use 0.1-10 mg of zinc hydroxide colloid, 10-1000 μg of lanolin, 10-1000 μg of bacterial lipopolysaccharide, and 10-1000 μg of Tween-8010-1000 μg. Adopting the compound adjuvant of the present invention greatly improves the immune response time, rapidly produces neutralization, and has a longer duration of immunity, and the preparation process is simple, the required equipment is easy to obtain, the industrial production cost is greatly reduced, and the stability of the obtained rabies vaccine is also improved. Greatly improve.

The invention provides a porcine circovirus 2 and porcine circovirus 3 bivalent inactivated vaccine and a preparation method thereof. The bivalent inactivated vaccine comprises inactivated porcine circovirus 2 and 3 and a vaccine adjuvant, wherein the content of the porcine circovirus 2 and 3 is respectively at least 105.5 TCID50 / piece. The bivalent inactivated vaccine disclosed by the invention has the following advantages that the immune effect of the porcine circovirus 2 is equivalent to or better than that of a commercial vaccine, a porcine circovirus 3 commercial vaccine does not exist inthe market, and two antigens do not interfere with each other; the immune duration is long, and the efficacy is lasting; and only one shot immunization is needed, the cost is reduced, and stress reactions of animals are reduced. The bivalent inactivated vaccine disclosed by the invention can be applied to simultaneously preventing the porcine circovirus 2 and 3.

The invention relates to a bivalent inactivated vaccine for bovine Pasteurella multocida and belongs to the technical field of preparation of veterinary biological products. The bivalent inactivated vaccine of the present invention is composed of an antigen and a vaccine adjuvant, wherein the antigen is the Pasteurella multocida capsular type A Pm-TJ strain and the Pasteurella multocida capsular type B C45-2 strain. The bivalent inactivated vaccine prepared by the present invention adopts a concentration and purification process, and optimizes the fermentation and cultivation process of the Pasteurella multocida capsular B type C45-2 strain, which shortens the fermentation time by more than half and improves production efficiency. The invented bivalent inactivated vaccine can simultaneously prevent bovine fibrinous suppurative pneumonia and bovine hemorrhagic sepsis caused by Pasteurella multocida infection through one-shot immunization, and has the characteristics of safety, reliability and good immune effect.